Genomic analyses do not always reliably predict the expression and functionality needed for protein-targeted therapies. CellCarta’s proteomic services provide you with comprehensive options for protein quantification in clinical samples.
Our immuno-MRM platform is uniquely able to capture the advantages of quantitative mass spectrometry. Utilizing target-specific affinity reagents and immuno-MRM proof-of-concept data, our platform enables highly flexible assays for oncology clinical trials.
With our immuno-MRM assays, our clients obtain the advantage of protein quantification via multiple reaction monitoring (MRM) technology to confidently quantify specific target fragments in clinical samples.
Why choose immuno-MRM assays for clinical application?
What is CellCarta’s advantage?
With the exclusive acquisition of Precision Assays’ assets in 2022, we provide the latest in immuno-MRM panels. Dr. Paulovich, founder of Precision Assays, is a pioneer in multiplex, quantitative protein biomarker measurements by mass spectrometry.
Dr. Paulovich’s research has advanced the tools for quantifying human proteins, setting best-in-class standards to support precision medicine studies in cancer-specific protein expression analysis in a variety of matrices from FFPE cancer tissue biopsies to clinical serum-based samples.